TNYA

#3733
Tenaya Therapeutics, Inc. - Common Stock
0.6 9 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.69
0.71
Jahresspanne
0.53
2.35
Tagesänderung
-1.43%
Monatliche Änderung
-6.76%
6 month change
+21.05%
Jahresänderung
-41.03%
Vorheriger Schlusskurs
0.7 0
Open
0.7 0
Tief
0.6 9
Hoch
0.7 1
Volumen
153
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Tenaya Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Tenaya Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Tenaya Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Tenaya Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Tenaya Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Tenaya Therapeutics, Inc. current report, Q1 FY2026
8-K

Tenaya Therapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

Tenaya Therapeutics, Inc. (TNYA) filed a Form 8-K on June 29, 2026, reporting the termination of a material definitive agreement. The Company is an emerging growth company focused on genetic medicines, with principal executive offices in South San Francisco, California.

Key Financial Metrics

This filing does not report revenue, profit, cash flow, margins, or overall debt levels. The specific financial impact disclosed relates to the lease termination:

  • Security Deposit Forfeiture: $1,750,000
  • One-time Lease Termination Fee: Approximately $294,200
  • Total Immediate Cost: Approximately $2,044,200

Material Changes

The Company terminated its lease for the Genetic Medicines Manufacturing Center (GMMC Facility) in Union City, California, effective August 31, 2026. This facility, comprising approximately 94,046 rentable square feet, was originally scheduled to expire in July 2031. The GMMC Facility was decommissioned in 2025 as a cost-reduction measure. The early termination is feasible due to sufficient existing inventory of TN-201 and TN-401 to support ongoing clinical trials.

Outlook, Management Commentary, and Risks

Management indicated that the Company has retained its internal process and assay development know-how. Future AAV manufacturing will be transferred to a contract development manufacturing organization (CDMO) with global capabilities to support late-stage development and potential commercial launch of TN-201 and TN-401. The filing does not provide updated financial guidance or discuss new risks beyond the operational shift to CDMOs.

Key Facts for Investor Verification

  • Verify the total cash outflow of approximately $2.04 million associated with the lease termination.
  • Confirm the timeline and terms of the new manufacturing agreement with the selected CDMO.
  • Assess the sufficiency of current TN-201 and TN-401 inventory levels to sustain clinical trials without in-house manufacturing.
  • Review the impact of the facility closure on future operational flexibility and cost structure.

Nachrichten